Sign In
Buy MRSN
$29.08
+0 (+0%)
At Close: Apr 02, 2026
Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results
07:00am, Thursday, 15'th May 2025
CAMBRIDGE, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on developing a pipeline of antibody-drug conjugates (A
CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on developing a pipeline of antibody-drug conjugates (A
Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting
10:12am, Wednesday, 23'rd Apr 2025
CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 04'th Apr 2025
CAMBRIDGE, Mass., April 04, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d
CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates
09:10am, Monday, 03'rd Mar 2025
Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.16 per share a year ago.
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results
07:01am, Monday, 03'rd Mar 2025
CAMBRIDGE, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-
Mersana Therapeutics to Present at Upcoming Investor Conferences
08:00am, Tuesday, 25'th Feb 2025
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d
Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025
04:01pm, Monday, 24'th Feb 2025
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 07'th Feb 2025
CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dr
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
08:00am, Thursday, 30'th Jan 2025
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d
Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?
12:49pm, Friday, 10'th Jan 2025
On Friday, Mersana Therapeutics Inc. MRSN released initial data from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin.
Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)
06:02am, Friday, 10'th Jan 2025
Conference call to discuss positive initial Phase 1 clinical data today at 8:30 a.m. ET Conference call to discuss positive initial Phase 1 clinical data today at 8:30 a.m. ET
- Emiltatug ledadotin observed to be generally well tolerated with differentiated safety and tolerability profile - Promising clinical activity observed in patients with triple-negative breast cancer
Mersana Therapeutics: We're About To Find Out If ADC Platform Is More Tolerable
07:17am, Thursday, 19'th Dec 2024
Mersana Therapeutics is developing novel antibody-drug conjugates targeting a heretofore untapped immune checkpoint, as well as HER2 from another angle. The company has an operational runway of 6-7 qu
